---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-221863"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2025-09-29T23:59:59+00:00"
generated_at: "2026-05-17T05:26:27.005972+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics appoints trauma expert Col. (Ret.) John Holcomb to Board

## Summary
- Dr. John Holcomb elected as Class II director; term expires at 2026 annual meeting.
- Option granted for 4,174 shares vesting over three years under 2021 Equity Plan.
- Holcomb served 23 years in U.S. Army, pioneered combat casualty care; 780+ publications.
- Appointment aims to advance iNKT therapies into immune-mediated disease and pulmonary disorders.

## SEC filing metadata
- accession: 0001193125-25-221863
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2025-09-29T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000119312525221863/0001193125-25-221863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000119312525221863/inkt-20250923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-221863
- JSON: https://secwatch.observer/filing/0001193125-25-221863.json
- Plain text: https://secwatch.observer/filing/0001193125-25-221863.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.